Loading
NASDAQHealthcareBiotechnology
Latest quote
$24.04
+$0.01 · +0.04%
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Previous close
$24.04
+$0.01 · +0.04%
After-hours
$24.04
$0.00 · 0.00%
Sep 10, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Day range
Current $24.04
52-week range
Current $24.04
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
75
Undervalued
Sentiment
65
Bullish
Risk
62
High Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Day range
Current $24.04
52-week range
Current $24.04
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 812.03M USD | 412.26M USD | 306.13M USD | 258.49M USD | 294.01M USD |
| Cost of goods sold | 272.87M USD | 233.48M USD | 216.82M USD | 178.46M USD | 109.86M USD |
| Gross profit | 539.17M USD | 178.78M USD | 89.31M USD | 80.02M USD | 184.16M USD |
| Research and development | 45.31M USD | 113.92M USD | 116.88M USD | 101.27M USD | — |
| Selling, general, and administrative | 392.47M USD | 321.86M USD | 291.48M USD | 294.51M USD | 27.31M USD |
| Operating expenses | 494.06M USD | 435.9M USD | 408.86M USD | 395.78M USD | 45.07M USD |
| Interest income | 16.5M USD | 7.12M USD | 11.26M USD | 947K USD | — |
| Interest expense | 56.85M USD | 50.03M USD | 31.61M USD | 26.68M USD | 61.57M USD |
| Depreciation and amortization | 22.62M USD | 48.91M USD | 49M USD | 48.25M USD | 110.65M USD |
| Operating income | 45.11M USD | −257.12M USD | −319.55M USD | −315.76M USD | 139.09M USD |
| Net income | −537.96M USD | −281.89M USD | −341.42M USD | −320.83M USD | 27.73M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$26.00
8.15% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI63.73M0.00%2.3T USD0.03%$373.24-0.62%
Vanguard Morningstar Small-Cap ETFVB45.83M0.02%183.4B USD0.03%$291.18-0.99%
Vanguard Morningstar Small-Cap Growth ETFVBK26.48M0.06%43.8B USD0.05%$337.98-1.41%
iShares Biotechnology ETFIBB22.4M0.21%10.3B USD0.44%$202.64-1.39%
iShares Russell Mid-Cap Growth ETFIWP14.97M0.08%19.19B USD0.23%$136.68-1.28%
iShares Russell Mid-Cap ETFIWR12.24M0.02%55.58B USD0.18%$108.96-0.89%
iShares Russell 1000 Growth ETFIWF9.79M0.01%123.81B USD0.18%$121.32-0.93%
iShares Genomics Immunology and Healthcare ETFIDNA7.21M2.81%251.49M USD0.47%$37.88-1.87%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPiShares Russell Mid-Cap ETFIWRiShares Russell 1000 Growth ETFIWFiShares Genomics Immunology and Healthcare ETFIDNAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
